Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21044799rdf:typepubmed:Citationlld:pubmed
pubmed-article:21044799lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:21044799lifeskim:mentionsumls-concept:C1332128lld:lifeskim
pubmed-article:21044799lifeskim:mentionsumls-concept:C0597198lld:lifeskim
pubmed-article:21044799lifeskim:mentionsumls-concept:C1450054lld:lifeskim
pubmed-article:21044799lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:21044799pubmed:issue3lld:pubmed
pubmed-article:21044799pubmed:dateCreated2010-11-24lld:pubmed
pubmed-article:21044799pubmed:abstractTextCarcinomatosis from peritoneal surface malignancies, such as mesothelioma, appendiceal carcinoma or ovarian metastases, significantly decreases survival and quality of life. Given a 60-80% locoregional recurrence rate after surgical debulking for mesothelioma, the current study explores the use of polymeric nanoparticles, specifically engineered to expand and locally deliver chemotherapeutic agents at endosomal pH, for the prevention of progressive carcinomatosis. Anti-tumor efficacy of paclitaxel-loaded pH-responsive expansile nanoparticles (Pax-eNP) was evaluated in vitro and in in vivo murine models of malignant peritoneal mesothelioma. Pax-eNP inhibited mesothelioma growth in vitro, markedly decreased tumor growth and disease severity in vivo, prevented initial intraperitoneal tumor implants, and significantly prolonged survival compared to other intraperitoneal drug delivery methods. These outcomes suggest that the mechanism of pH-triggered drug delivery and tumor affinity associated with eNP may effectively improve the local control of residual microscopic disease following surgical debulking of locoregionally aggressive malignancies.lld:pubmed
pubmed-article:21044799pubmed:languageenglld:pubmed
pubmed-article:21044799pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21044799pubmed:citationSubsetIMlld:pubmed
pubmed-article:21044799pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21044799pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21044799pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21044799pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21044799pubmed:statusMEDLINElld:pubmed
pubmed-article:21044799pubmed:monthJanlld:pubmed
pubmed-article:21044799pubmed:issn1878-5905lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:ToyaMMlld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:GrinstaffMark...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:PaderaRobert...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:ColsonYolonda...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:ZubrisKimberl...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:GrisetAaron...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:SchulzMorgan...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:SouthardEmily...lld:pubmed
pubmed-article:21044799pubmed:authorpubmed-author:WadeJacquelin...lld:pubmed
pubmed-article:21044799pubmed:copyrightInfoCopyright © 2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:21044799pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21044799pubmed:volume32lld:pubmed
pubmed-article:21044799pubmed:ownerNLMlld:pubmed
pubmed-article:21044799pubmed:authorsCompleteYlld:pubmed
pubmed-article:21044799pubmed:pagination832-40lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:meshHeadingpubmed-meshheading:21044799...lld:pubmed
pubmed-article:21044799pubmed:year2011lld:pubmed
pubmed-article:21044799pubmed:articleTitleThe performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis.lld:pubmed
pubmed-article:21044799pubmed:affiliationDivision of Thoracic Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA. ycolson@partners.orglld:pubmed
pubmed-article:21044799pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21044799pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed